1-20 of 3117 Search Results for

ab-antibody

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Meeting Abstracts
Journal: Diabetes
Diabetes 2019;68(Supplement_1):1331-P
Published: 01 June 2019
..., the prevalence of these GRCs differ in diabetic and nondiabetic individuals (Table). While islet cell Ab- obese youth CDX-T2D have worse IS, Ab+ youth have severe impairment in BCF [Diabetes 58: 2009]. Here, we examined the prevalence of OGTT-GRC patterns, clamp-measured IS, and BCF...
Meeting Abstracts
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1688-P
Published: 01 July 2018
... in 709 Ab+ Diabetes Prevention Trial-type 1 participants with 2-hour OGTTs [mean age: 13.9±9.6 years; BMI percentile (%ile): 59.3±29.0; 56% male]. Log rank testing and Cox regression with adjustments for age, sex, BMI %ile, proband relation, HLA, and Ab number were used. Risks were higher for time...
Meeting Abstracts
Journal: Diabetes
Diabetes 2019;68(Supplement_1):1668-P
Published: 01 June 2019
..., but phenotypic differences are not well characterised. We investigated ethnic group differences in the clinical characteristics and antibody (Ab) status at clinical onset of T1D. Methods: We studied people of white European (WE), Asian (A) and black African/Caribbean (AC) ethnicity with clinically-assigned T1D...
Images
Anti–TGF-β and anti–PD-1 dual <span class="search-highlight">antibody</span> (<span class="search-highlight">ab</span>) treatment render NOD.ChgA<sup>−</sup>...
Published: 08 September 2021
Figure 4 Anti–TGF-β and anti–PD-1 dual antibody (ab) treatment render NOD.ChgA−/− mice susceptible to autoimmune diabetes. A: Representative FACS plots showing the percentage of indicated immune cell populations in the islets of NOD.ChgA−/− mice either treated with four injections of anti–TGF-β ab every 3 days or left untreated (control). Infiltration of leukocytes was analyzed 15 days postinitiation of treatment. B: Quantification of the percentage of indicated cell populations among total islet cells as described in panel A. Data (mean ± SEM) are pooled from three independent experiments. Each dot represents individual mouse. C: Experimental design of the anti–TGF-β and anti–PD-1 ab treatment. D: Incidence of diabetes in 8–10 week old NOD or NOD.ChgA−/− mice treated with anti–TGF-β either alone or in combination with anti–PD-1. Data are pooled from three independent experiments. P values were calculated by unpaired two-tailed Student t test. *P < 0.05. DC, dendritic cell; ns, not significant. More
Images
The GCGR monoclonal <span class="search-highlight">antibody</span> <span class="search-highlight">Ab</span>-4 blocks glucagon activity at the mouse GCG...
Published: 06 October 2014
Figure 2 The GCGR monoclonal antibody Ab-4 blocks glucagon activity at the mouse GCGR. A: Glucagon-induced cAMP accumulation in HEK293 cells expressing the mouse GGCR is inhibited by Ab-4 (Kb = 0.76 nmol/L). B: Ab-4 does not inhibit GLP-1-induced cAMP accumulation in HEK293 cells expressing the mouse GLP-1R. Figure 2. The GCGR monoclonal antibody Ab-4 blocks glucagon activity at the mouse GCGR. A: Glucagon-induced cAMP accumulation in HEK293 cells expressing the mouse GGCR is inhibited by Ab-4 (Kb = 0.76 nmol/L). B: Ab-4 does not inhibit GLP-1-induced cAMP accumulation in HEK293 cells expressing the mouse GLP-1R. More
Images
BAFF-deficient (BAFF<sup>null</sup>) and anti-BAFF <span class="search-highlight">antibody</span> (<span class="search-highlight">Ab</span>)–treated ob...
Published: 22 September 2014
Figure 4 BAFF-deficient (BAFFnull) and anti-BAFF antibody (Ab)–treated obese mice exhibit superior glucose metabolic control compared with WT and Bnull mice. Body weights (A), GTT with AUC (B), and ITT (C) of HFD WT, BAFFnull, and Bnull mice (n = 5). GTT with AUC (D), body weights (E), and fasting insulin (F) of HFD WT mice 4 weeks after they received anti-BAFF antibody or isotype control (n = 5). IgG concentration in serum (G) and VAT lysate (H) 5 weeks after anti-BAFF antibody treatment (n = 5). Cytokine concentrations in 24-h cultures of PerC (I) or spleen (J) cells stimulated with LPS from isotype control and BAFF antibody–treated mice (n = 5). K: mRNA expression in VAT from isotype control and BAFF antibody–treated mice (n = 4). Values are given as mean ± SEM. *P < 0.05; **P < 0.005; ***P < 0.0005. Figure 4. BAFF-deficient (BAFFnull) and anti-BAFF antibody (Ab)–treated obese mice exhibit superior glucose metabolic control compared with WT and Bnull mice. Body weights (A), GTT with AUC (B), and ITT (C) of HFD WT, BAFFnull, and Bnull mice (n = 5). GTT with AUC (D), body weights (E), and fasting insulin (F) of HFD WT mice 4 weeks after they received anti-BAFF antibody or isotype control (n = 5). IgG concentration in serum (G) and VAT lysate (H) 5 weeks after anti-BAFF antibody treatment (n = 5). Cytokine concentrations in 24-h cultures of PerC (I) or spleen (J) cells stimulated with LPS from isotype control and BAFF antibody–treated mice (n = 5). K: mRNA expression in VAT from isotype control and BAFF antibody–treated mice (n = 4). Values are given as mean ± SEM. *P < 0.05; **P < 0.005; ***P < 0.0005. More
Images
HMGB1 <span class="search-highlight">antibody</span> (<span class="search-highlight">Ab</span>) treatment regulates T-cell subpopulations. PLN and sple...
Published: 01 August 2008
FIG. 7. HMGB1 antibody (Ab) treatment regulates T-cell subpopulations. PLN and splenic T-cells originated from HMGB1 antibody–treated mice and control mice were harvested for intracellular IFN-γ staining. The percentages of CD4+ and CD8+ T-cells that are also positive for IFN-γ were determined by flow cytometric analysis. The data are presented in the table as means ± SD of three independent experiments performed. The number of CD8+IFN-γ+ T-cells (Tc1) in the PLN of antibody-treated animals was significantly higher than that of control animals (P < 0.01). A similar trend was also observed in the splenic T-cells. *P < 0.01. FIG. 7. HMGB1 antibody (Ab) treatment regulates T-cell subpopulations. PLN and splenic T-cells originated from HMGB1 antibody–treated mice and control mice were harvested for intracellular IFN-γ staining. The percentages of CD4+ and CD8+ T-cells that are also positive for IFN-γ were determined by flow cytometric analysis. The data are presented in the table as means ± SD of three independent experiments performed. The number of CD8+IFN-γ+ T-cells (Tc1) in the PLN of antibody-treated animals was significantly higher than that of control animals (P < 0.01). A similar trend was also observed in the splenic T-cells. *P < 0.01. More
Images
The effect of addition of anti-TIMP-1 <span class="search-highlight">antibody</span> (<span class="search-highlight">Ab</span>) (<em>A</em>) an...
Published: 01 August 2002
FIG. 5. The effect of addition of anti-TIMP-1 antibody (Ab) (A) and anti-TIMP-2 antibody (B) on the degradation of [35S]methionine radiolabeled mesangium matrix. Results are disintegrations per minute released to the culture media expressed as percentage of the total amount of count in the matrix. * P < 0.05, significantly different from corresponding samples without the addition of antibodies. FIG. 5. The effect of addition of anti-TIMP-1 antibody (Ab) (A) and anti-TIMP-2 antibody (B) on the degradation of [35S]methionine radiolabeled mesangium matrix. Results are disintegrations per minute released to the culture media expressed as percentage of the total amount of count in the matrix. * P < 0.05, significantly different from corresponding samples without the addition of antibodies. More
Journal Articles
Journal: Diabetes
Diabetes 1997;46(6):937–940
Published: 01 June 1997
... antibodies (Abs) were capable of neutralizing the IL-1β produced, and the effect persisted for at least 5 days. Second, we evaluated the role of IL-1β in the cyclophosphamide (CY)-accelerated model of diabetes. Nondiabetic male NOD mice were injected with 200 mg/kg CY and treated twice weekly with anti–IL-1β...
Images
Univariate HRs for <span class="search-highlight">antibody</span> increase. All factors analyzed are depicted. ■,...
Published: 16 April 2013
FIG. 5. Univariate HRs for antibody increase. All factors analyzed are depicted. ■, HR; line, 95% CI; □, P < 0.05. Ab, antibody; IE, islet equivalents; Ln, natural logarithm; pre-Tx, pretransplant. FIG. 5. Univariate HRs for antibody increase. All factors analyzed are depicted. ■, HR; line, 95% CI; □, P < 0.05. Ab, antibody; IE, islet equivalents; Ln, natural logarithm; pre-Tx, pretransplant. More
Images
Inhibitory effect of β1 integrin <span class="search-highlight">antibody</span> on β-cell spreading. β-Cells in s...
Published: 01 May 2006
FIG. 5. Inhibitory effect of β1 integrin antibody on β-cell spreading. β-Cells in suspension were pretreated with 2 μg/ml Ha2/5 antibody (Ab), 2 μg/ml hamster IgM, or BSA (without antibody) for 1 h and then plated on poly-l-lysine (PLL)- or 804G matrix (Mx)-coated dishes in continuous presence of the antibody. Cells were fixed 5 h later. Cell area profile was measured, using ScionImage software. n = 3–4 with >100 cells analyzed per experiment. *P < 0.02 vs. poly-l-lysine control; **P < 0.04 vs. 804G matrix control. Ab, antibody; w/o, without. FIG. 5. Inhibitory effect of β1 integrin antibody on β-cell spreading. β-Cells in suspension were pretreated with 2 μg/ml Ha2/5 antibody (Ab), 2 μg/ml hamster IgM, or BSA (without antibody) for 1 h and then plated on poly-l-lysine (PLL)- or 804G matrix (Mx)-coated dishes in continuous presence of the antibody. Cells were fixed 5 h later. Cell area profile was measured, using ScionImage software. n = 3–4 with >100 cells analyzed per experiment. *P < 0.02 vs. poly-l-lysine control; **P < 0.04 vs. 804G matrix control. Ab, antibody; w/o, without. More
Images
HPAP workflow. HPAP, working with nPOD, identifies organ donors of interest...
Published: 24 May 2019
Figure 1 HPAP workflow. HPAP, working with nPOD, identifies organ donors of interest (recent-onset type 1 diabetes, antibody-positive donors, and control subjects). For organ donors <30 years old without diabetes, the OPO, using HPAP/nPOD protocols and reagents, screens for presence of GADAs. I... More
Journal Articles
Journal: Diabetes
Diabetes 1996;45(6):795–800
Published: 01 June 1996
..., membrane preparations of RIN cells and human pancreas, and three control antigens (La = nuclear cell antigen, tetanus toxoid, and phytohemagglutinin). A total of 28 patients with newly diagnosed IDDM, 9 antibody-positive (Ab+) first-degree relatives, and 16 healthy control subjects were included. Increased...
Images
BRD2 and 4 are proximally bound to Ins1 promoter in MIN6 cells. ChIP of BRD...
Published: 17 January 2019
Figure 6 BRD2 and 4 are proximally bound to Ins1 promoter in MIN6 cells. ChIP of BRD2, 3, and 4 in MIN6 cells that were treated for 24 h with 0.1% DMSO or 1 μmol/L JQ1. The precipitated chromatin was analyzed by real-time PCR and is expressed as a percentage of the input chromatin signal. Data are mean ± SD of at least three independent experiments. *P ≤ 0.05, **P ≤ 0.01. Ab, antibody; kb, kilobase. Figure 6. BRD2 and 4 are proximally bound to Ins1 promoter in MIN6 cells. ChIP of BRD2, 3, and 4 in MIN6 cells that were treated for 24 h with 0.1% DMSO or 1 μmol/L JQ1. The precipitated chromatin was analyzed by real-time PCR and is expressed as a percentage of the input chromatin signal. Data are mean ± SD of at least three independent experiments. *P ≤ 0.05, **P ≤ 0.01. Ab, antibody; kb, kilobase. More
Images
ACAM Tg mice are resistant to obesity. <em>A</em>: WT and ACAM Tg m...
Published: 08 March 2016
Figure 1 ACAM Tg mice are resistant to obesity. A: WT and ACAM Tg male C57BL/6JJcl mice were fed HFHS and standard chow (STD). B: Fat pad weight of WT and ACAM Tg mice at 30 weeks of age. C: The average size of adipocytes in epididymal adipose tissues of WT and ACAM Tg mice on HFHS diet. The size distribution of adipocytes (D), periodic acid Schiff staining (E, left panels), scanning electron micrographs (E, right panels), immunofluorescence (F, left panels), and immunoperoxidase staining (F, right panels) with ACAM Ab (antibody) and double immunofluorescence staining of F4/80 and ACAM Ab (G) in epididymal adipose tissues of WT and ACAM Tg mice on HFHS diet. All data are presented as mean ± SE. n = 8. *P < 0.05 vs. WT mice. w, weeks. Figure 1. ACAM Tg mice are resistant to obesity. A: WT and ACAM Tg male C57BL/6JJcl mice were fed HFHS and standard chow (STD). B: Fat pad weight of WT and ACAM Tg mice at 30 weeks of age. C: The average size of adipocytes in epididymal adipose tissues of WT and ACAM Tg mice on HFHS diet. The size distribution of adipocytes (D), periodic acid Schiff staining (E, left panels), scanning electron micrographs (E, right panels), immunofluorescence (F, left panels), and immunoperoxidase staining (F, right panels) with ACAM Ab (antibody) and double immunofluorescence staining of F4/80 and ACAM Ab (G) in epididymal adipose tissues of WT and ACAM Tg mice on HFHS diet. All data are presented as mean ± SE. n = 8. *P < 0.05 vs. WT mice. w, weeks. More
Images
Neutralization of MIF stimulates INS-1 cell proliferation. INS-1 cells (1 ×...
Published: 01 June 2002
FIG. 4. Neutralization of MIF stimulates INS-1 cell proliferation. INS-1 cells (1 × 105) were synchronized by overnight incubation in serum-free RPMI-1640 medium with 2.5 mmol/l glucose and 0.1% BSA. Glucose (11 mmol/l) was added to synchronized cells with anti-MIF monoclonal antibody or an isotype control monoclonal antibody (Con IgG). Cell proliferation rate was assessed by [3H]thymidine incorporation. Data are means ± se of triplicate assays from three separate experiments. **P < 0.001. Ab, antibody. FIG. 4. Neutralization of MIF stimulates INS-1 cell proliferation. INS-1 cells (1 × 105) were synchronized by overnight incubation in serum-free RPMI-1640 medium with 2.5 mmol/l glucose and 0.1% BSA. Glucose (11 mmol/l) was added to synchronized cells with anti-MIF monoclonal antibody or an isotype control monoclonal antibody (Con IgG). Cell proliferation rate was assessed by [3H]thymidine incorporation. Data are means ± se of triplicate assays from three separate experiments. **P < 0.001. Ab, antibody. More
Images
Inhibitory effect of anti–laminin-5 <span class="search-highlight">antibody</span> on β-cell spreading and insuli...
Published: 01 May 2006
FIG. 3. Inhibitory effect of anti–laminin-5 antibody on β-cell spreading and insulin secretion. Petri dishes coated with poly-l-lysine or 804G matrix (Mx) were treated with anti–laminin-5 (CM6 antibody), anti-fibronectin (fibronectin antibody), mouse IgG, or PBS-BSA (without antibody). β-Cells were incubated on these dishes for 24 h. A: Phase-contrast microscopic views. Bar = 100 μm. B: Insulin secretion in response to 2.8 and 16.7 mmol/l glucose (n = 3–5). *P < 0.05 vs. poly-l-lysine (PLL) in respective condition; **P < 0.001 vs. 804G matrix control. Ab, antibody; w/o, without. FIG. 3. Inhibitory effect of anti–laminin-5 antibody on β-cell spreading and insulin secretion. Petri dishes coated with poly-l-lysine or 804G matrix (Mx) were treated with anti–laminin-5 (CM6 antibody), anti-fibronectin (fibronectin antibody), mouse IgG, or PBS-BSA (without antibody). β-Cells were incubated on these dishes for 24 h. A: Phase-contrast microscopic views. Bar = 100 μm. B: Insulin secretion in response to 2.8 and 16.7 mmol/l glucose (n = 3–5). *P < 0.05 vs. poly-l-lysine (PLL) in respective condition; **P < 0.001 vs. 804G matrix control. Ab, antibody; w/o, without. More
Images
SK2 and -3 protein expression in mouse pancreatic islets. Shown is a Wester...
Published: 01 August 2003
FIG. 2. SK2 and -3 protein expression in mouse pancreatic islets. Shown is a Western blot of protein extracts of mouse islets with: anti-SK2 (lane 1), anti-SK2 with antigenic SK2 peptide (lane 2), anti-SK3 (lane 3), and anti-SK3 with antigenic SK3 peptide (lane 4). Note the bands corresponding to SK2 (60 kDa) and SK3 (70 kDa). Ab, antibody. FIG. 2. SK2 and -3 protein expression in mouse pancreatic islets. Shown is a Western blot of protein extracts of mouse islets with: anti-SK2 (lane 1), anti-SK2 with antigenic SK2 peptide (lane 2), anti-SK3 (lane 3), and anti-SK3 with antigenic SK3 peptide (lane 4). Note the bands corresponding to SK2 (60 kDa) and SK3 (70 kDa). Ab, antibody. More
Images
UnAG and skeletal muscle inflammation. Effects of UnAG (200 μg subcutaneous...
Published: 28 January 2016
Figure 2 UnAG and skeletal muscle inflammation. Effects of UnAG (200 μg subcutaneous injection twice per day) vs. saline (Ct) sustained 4-day treatment on the expression of IκB (A), NF-κB binding activity (B) with representative blots, and tissue expression of IL-1α (C), IL-1β (D), TNF-α (E), IL-6 (F), and IL-10 (G) measured by xMAP technology in gastrocnemius muscle. Data are mean ± SEM (n = 8–10/group). *P < 0.05 vs. Ct. Ab, antibody; a.u., arbitrary units. Figure 2. UnAG and skeletal muscle inflammation. Effects of UnAG (200 μg subcutaneous injection twice per day) vs. saline (Ct) sustained 4-day treatment on the expression of IκB (A), NF-κB binding activity (B) with representative blots, and tissue expression of IL-1α (C), IL-1β (D), TNF-α (E), IL-6 (F), and IL-10 (G) measured by xMAP technology in gastrocnemius muscle. Data are mean ± SEM (n = 8–10/group). *P < 0.05 vs. Ct. Ab, antibody; a.u., arbitrary units. More
Images
VEGF neutralization in long-term high-fat–fed mice. <em>A</em>: Eig...
Published: 17 July 2014
Figure 3 VEGF neutralization in long-term high-fat–fed mice. A: Eight-week-old mice were placed on chow diet or HFD for 4 weeks and were administered a single injection of either VEGF-neutralizing or control antibody at days 0 and 3. Glucose tolerance was assessed (B) 3 days after the first single injection and again at (C) day 7, (D) day 11, (E) day 17, and (F) day 21. G: Glucose tolerance was quantified by measuring AUCs. n = 5–8 mice per group. *P < 0.05; **P < 0.01, Kruskal–Wallis test. Glucose levels are plotted as median values, and error bars are interquartile range. Ab, antibody; DXA, dual-energy X-ray absorptiometry; ITT, insulin tolerance test. Figure 3. VEGF neutralization in long-term high-fat–fed mice. A: Eight-week-old mice were placed on chow diet or HFD for 4 weeks and were administered a single injection of either VEGF-neutralizing or control antibody at days 0 and 3. Glucose tolerance was assessed (B) 3 days after the first single injection and again at (C) day 7, (D) day 11, (E) day 17, and (F) day 21. G: Glucose tolerance was quantified by measuring AUCs. n = 5–8 mice per group. *P < 0.05; **P < 0.01, Kruskal–Wallis test. Glucose levels are plotted as median values, and error bars are interquartile range. Ab, antibody; DXA, dual-energy X-ray absorptiometry; ITT, insulin tolerance test. More